The Korean journal of internal medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지
DOI QR코드

DOI QR Code

Efficacy and safety of tocilizumab in Korean patients with active rheumatoid arthritis

  • Received : 2017.04.18
  • Accepted : 2017.07.11
  • Published : 2019.07.01
⟨ Previous Next ⟩

Abstract

Background/Aims: To investigate the efficacy and safety of tocilizumab (TCZ) humanized anti-interleukin-6 receptor monoclonal antibody, in Korean patients with active rheumatoid arthritis (RA) refractory to conventional disease modifying anti-rheumatic drugs (DMARDs) including methotrexate (MTX) Methods: The main study was a 24-week, randomized, double-blind, controlled trial that was followed by a 48-week, open-labeled, extension phase. TCZ (8 mg/kg) or placebo was intravenously administered every 4 weeks. Results: Those treated with TCZ showed more favorable outcomes in terms of 20% according to the American College of Rheumatology response criteria (ACR20) and ACR50 responses, individual parameters of ACR core set, disease activity score in 28 joints (DAS28) remission, and European League Against Rheumatism (EULAR) response at week 24. These improvements were maintained or increased during the extension period. DAS28 remission at week 72 was associated with EULAR good response at week 12. The patients who experienced any adverse event (AE) were more frequent in the TCZ group compared to the placebo group. Most AEs were mild or moderate in intensity, although TCZ therapy had possible AEs including serious infection, abnormal liver function, and atherogenic lipid profile. Conclusions: TCZ infusion add-on is highly efficacious and well-tolerated in Korean patients with active RA refractory to conventional DMARDs including MTX. EULAR good response at week 12 could predict DAS28 remission at week 72.

Keywords

References

  1. Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001;344:907-916. https://doi.org/10.1056/NEJM200103223441207
  2. Smolen JS, Aletaha D, Koeller M, Weisman MH, Emery P. New therapies for treatment of rheumatoid arthritis. Lancet 2007;370:1861-1874. https://doi.org/10.1016/S0140-6736(07)60784-3
  3. Desroches M, Louis G, Gleizes A, Krzysiek R, Emilie D. Treatment failure with antagonists of TNF-α: mechanisms and implications for the care of patients. Eur Cytokine Netw 2010;21:226-231.
  4. Kishimoto T. Interleukin-6: discovery of a pleiotropic cytokine. Arthritis Res Ther 2006;8 Suppl 2:S2. https://doi.org/10.1186/ar1916
  5. Madhok R, Crilly A, Watson J, Capell HA. Serum interleukin 6 levels in rheumatoid arthritis: correlations with clinical and laboratory indices of disease activity. Ann Rheum Dis 1993;52:232-234. https://doi.org/10.1136/ard.52.3.232
  6. Mihara M, Kasutani K, Okazaki M, et al. Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family. Int Immunopharmacol 2005;5:1731-1740. https://doi.org/10.1016/j.intimp.2005.05.010
  7. Genovese MC, McKay JD, Nasonov EL, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum 2008;58:2968-2980. https://doi.org/10.1002/art.23940
  8. Nishimoto N, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Azuma J. Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study. Ann Rheum Dis 2009;68:1580-1584. https://doi.org/10.1136/ard.2008.092866
  9. Maini RN, Taylor PC, Szechinski J, et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 2006;54:2817-2829. https://doi.org/10.1002/art.22033
  10. Emery P, Keystone E, Tony HP, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicenter randomised placebo-controlled trial. Ann Rheum Dis 2008;67:1516-1523. https://doi.org/10.1136/ard.2008.092932
  11. Smolen JS, Beaulieu A, Rubbert-Roth A, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 2008;371:987-997. https://doi.org/10.1016/S0140-6736(08)60453-5
  12. Smolen JS, Landewe R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014;73:492-509.
  13. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-324. https://doi.org/10.1002/art.1780310302
  14. Joint Committee for the Development of Korean Guidelines for Tuberculosis, Korea Centers for Disease Control and Prevention. Korean Guidelines for Tuberculosis. Seoul: Korea Centers for Disease Control and Prevention, 2011.
  15. Paulus HE, Egger MJ, Ward JR, Williams HJ. Analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs, based on the findings in patients treated with placebo. The Cooperative Systematic Studies of Rheumatic Diseases Group. Arthritis Rheum 1990;33:477-484. https://doi.org/10.1002/art.1780330403
  16. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-48. https://doi.org/10.1002/art.1780380107
  17. van Gestel AM, Prevoo ML, van 't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum 1996;39:34-40. https://doi.org/10.1002/art.1780390105
  18. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23:137-145. https://doi.org/10.1002/art.1780230202
  19. Uppsala Monitoring Centre. The WHO adverse reaction terminology: WHO-ART [Internet]. Uppsala (SE): Uppsala Monitoring Centre, 2017 [cited 2017 Nov 7]. Available from: http://www.umc-products.com/graphics/28010.pdf.
  20. Yazici Y, Curtis JR, Ince A, et al. Efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis and a previous inadequate response to disease-modifying antirheumatic drugs: the ROSE study. Ann Rheum Dis 2012;71:198-205. https://doi.org/10.1136/ard.2010.148700
  21. Pers YM, Fortunet C, Constant E, et al. Predictors of response and remission in a large cohort of rheumatoid arthritis patients treated with tocilizumab in clinical practice. Rheumatology (Oxford) 2014;53:76-84. https://doi.org/10.1093/rheumatology/ket301
  22. Kojima T, Kaneko A, Hirano Y, et al. Early aggressive intervention with tocilizumab for rheumatoid arthritis increases remission rate defined using a Boolean approach in clinical practice. Mod Rheumatol 2012;22:370-375. https://doi.org/10.3109/s10165-011-0528-2
  23. Schiff MH, Kremer JM, Jahreis A, Vernon E, Isaacs JD, van Vollenhoven RF. Integrated safety in tocilizumab clinical trials. Arthritis Res Ther 2011;13:R141. https://doi.org/10.1186/ar3455
  24. Van der Meide PH, Schellekens H. Cytokines and the immune response. Biotherapy 1996;8:243-249. https://doi.org/10.1007/BF01877210
  25. Campbell L, Chen C, Bhagat SS, Parker RA, Ostor AJ. Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials. Rheumatology (Oxford) 2011;50:552-562. https://doi.org/10.1093/rheumatology/keq343
  26. Fujiwara H, Nishimoto N, Hamano Y, et al. Masked early symptoms of pneumonia in patients with rheumatoid arthritis during tocilizumab treatment: a report of two cases. Mod Rheumatol 2009;19:64-68. https://doi.org/10.3109/s10165-008-0111-7
  27. Nagabhushanam V, Solache A, Ting LM, Escaron CJ, Zhang JY, Ernst JD. Innate inhibition of adaptive immunity: Mycobacterium tuberculosis-induced IL-6 inhibits macrophage responses to IFN-gamma. J Immunol 2003;171:4750-4757. https://doi.org/10.4049/jimmunol.171.9.4750
  28. Ogata A, Mori M, Hashimoto S, et al. Minimal influence of tocilizumab on IFN-gamma synthesis by tuberculosis antigens. Mod Rheumatol 2010;20:130-133. https://doi.org/10.3109/s10165-009-0243-4
  29. Akira S, Taga T, Kishimoto T. Interleukin-6 in biology and medicine. Adv Immunol 1993;54:1-78. https://doi.org/10.1016/S0065-2776(08)60532-5
  30. Asensi V, Valle E, Meana A, et al. In vivo interleukin-6 protects neutrophils from apoptosis in osteomyelitis. Infect Immun 2004;72:3823-3828. https://doi.org/10.1128/IAI.72.7.3823-3828.2004
  31. Suwa T, Hogg JC, Quinlan KB, Van Eeden SF. The effect of interleukin-6 on L-selectin levels on polymorphonuclear leukocytes. Am J Physiol Heart Circ Physiol 2002;283:H879-H884. https://doi.org/10.1152/ajpheart.00185.2002
  32. Meune C, Touze E, Trinquart L, Allanore Y. Trends in cardiovascular mortality in patients with rheumatoid arthritis over 50 years: a systematic review and meta-analysis of cohort studies. Rheumatology (Oxford) 2009;48:1309-1313. https://doi.org/10.1093/rheumatology/kep252
  33. Martin-Martinez MA, Gonzalez-Juanatey C, Castaneda S, et al. Recommendations for the management of cardiovascular risk in patients with rheumatoid arthritis: scientific evidence and expert opinion. Semin Arthritis Rheum 2014;44:1-8. https://doi.org/10.1016/j.semarthrit.2014.01.002
  34. Robertson J, Peters MJ, McInnes IB, Sattar N. Changes in lipid levels with inflammation and therapy in RA: a maturing paradigm. Nat Rev Rheumatol 2013;9:513-523. https://doi.org/10.1038/nrrheum.2013.91
  35. Koike R, Harigai M, Atsumi T, et al. Japan College of Rheumatology 2009 guidelines for the use of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, in rheumatoid arthritis. Mod Rheumatol 2009;19:351-357. https://doi.org/10.3109/s10165-009-0197-6
  36. De Rycke L, Verhelst X, Kruithof E, et al. Rheumatoid factor, but not anti-cyclic citrullinated peptide antibodies, is modulated by infliximab treatment in rheumatoid arthritis. Ann Rheum Dis 2005;64:299-302. https://doi.org/10.1136/ard.2004.023523
  37. Bos WH, Bartelds GM, Wolbink GJ, et al. Differential response of the rheumatoid factor and anticitrullinated protein antibodies during adalimumab treatment in patients with rheumatoid arthritis. J Rheumatol 2008;35:1972-1977.
  38. Mikuls TR, O'Dell JR, Stoner JA, et al. Association of rheumatoid arthritis treatment response and disease duration with declines in serum levels of IgM rheumatoid factor and anti-cyclic citrullinated peptide antibody. Arthritis Rheum 2004;50:3776-3782. https://doi.org/10.1002/art.20659
  39. Epis O, Alpini C, Marceglia S, Casu C, Giacomelli L, Bruschi E. Clinical and serological response to tocilizumab in patients with rheumatoid arthritis. J Med Diagn Methods 2013;2:127.
  40. Anolik JH, Ravikumar R, Barnard J, et al. Cutting edge: anti-tumor necrosis factor therapy in rheumatoid arthritis inhibits memory B lymphocytes via effects on lymphoid germinal centers and follicular dendritic cell networks. J Immunol 2008;180:688-692. https://doi.org/10.4049/jimmunol.180.2.688
  41. Dougados M, Kissel K, Sheeran T, et al. Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY). Ann Rheum Dis 2013;72:43-50. https://doi.org/10.1136/annrheumdis-2011-201282

Cited by

  1. Tocilizumab Increases Body Weight and Serum Adipokine Levels in Patients with Rheumatoid Arthritis Independently of Their Treatment Response: a Retrospective Cohort Study vol.35, pp.22, 2019, https://doi.org/10.3346/jkms.2020.35.e155
  2. Severe prolonged neutropenia following administration of tocilizumab in a patient affected by COVID-19: a case report and brief review of the literature vol.36, pp.12, 2019, https://doi.org/10.1007/s40267-020-00777-z